Edward Lifesciences was downgraded to market perform at Leerink. $105 price target. Sales ramp may be slower than expected, Leerink said.
Tesoro (TSO) was upgraded to overweight from neutral at JPMorgan. $99 price target. Tesoro was also added to the Analyst Focus List. The valuation is more attractive, as the stock has lagged since the election, JPMorgan said.